Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 276

Similar articles for PubMed (Select 9651421)

1.

A phase I/II study of the protease inhibitor indinavir in children with HIV infection.

Mueller BU, Sleasman J, Nelson RP Jr, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwerski S, Sei S, Wood LV, Zeichner S, Pizzo PA.

Pediatrics. 1998 Jul;102(1 Pt 1):101-9.

PMID:
9651421
2.

The changes in bone organic and inorganic matrix in newborn rats after maternal application of antiretroviral agents: Indinavir and zidovudine.

Maciejewska K, Drzazga Z, Kaszuba M.

Biofactors. 2015 May 6;41(3):198-208. doi: 10.1002/biof.1215. Epub 2015 Jun 3.

PMID:
26040542
3.

Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs.

Imperiale JC, Nejamkin P, Del Sole MJ, E Lanusse C, Sosnik A.

Biomaterials. 2015 Jan;37:383-94. doi: 10.1016/j.biomaterials.2014.10.026. Epub 2014 Oct 25.

PMID:
25453966
4.

In vivo assessment of antiretroviral therapy-associated side effects.

Ramos-Sanchez EM, Goto H, Rivero DH, Mauad T, de Souza FN, Monteiro AM, Gidlund M.

Mem Inst Oswaldo Cruz. 2014 Jul;109(4):484-7.

5.

Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load.

Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y.

AIDS. 2012 Aug 24;26(13):1726-8. doi: 10.1097/QAD.0b013e32835646fb. No abstract available.

PMID:
22874480
6.

Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.

Endsley AN, Ho RJ.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):417-24. doi: 10.1097/QAI.0b013e3182653c1f.

7.

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team.

Clin Pharmacol Ther. 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21.

PMID:
22190066
8.

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Jann MW, Spratlin V, Momary K, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg C.

Eur J Clin Pharmacol. 2012 May;68(5):715-21. doi: 10.1007/s00228-011-1180-7. Epub 2011 Dec 16.

PMID:
22173281
9.

Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongkol O, Aurpibul L, Kabat B, Toye M, Smith ME, Eksaengsri A, McIntosh K, Yogev R; IMPAACT P1069 Team.

Antivir Ther. 2011;16(8):1287-95. doi: 10.3851/IMP1931.

10.

[Evidence-based therapeutic drug monitoring for indinavir].

Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review. French.

PMID:
21819808
11.

Brain delivery of transferrin coupled indinavir submicron lipid emulsions--pharmacokinetics and tissue distribution.

Prabhakar K, Afzal SM, Kumar PU, Rajanna A, Kishan V.

Colloids Surf B Biointerfaces. 2011 Sep 1;86(2):305-13. doi: 10.1016/j.colsurfb.2011.04.013. Epub 2011 Apr 20.

PMID:
21565469
12.

Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

Kasserra C, O'Mara E.

Clin Pharmacokinet. 2011 Apr;50(4):267-80. doi: 10.2165/11584560-000000000-00000.

PMID:
21348539
13.

Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.

Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, Benech H, Roques P, Le Grand R.

Retrovirology. 2010 Sep 26;7:78. doi: 10.1186/1742-4690-7-78.

14.

Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy.

Huynh J, Hever A, Tom T, Sim JJ.

Int Urol Nephrol. 2011 Jun;43(2):571-3. doi: 10.1007/s11255-010-9751-6. Epub 2010 May 11.

15.

Dynamic calibration of pharmacokinetic parameters in dose-finding studies.

O'Quigley J, Hughes MD, Fenton T, Pei L.

Biostatistics. 2010 Jul;11(3):537-45. doi: 10.1093/biostatistics/kxq002. Epub 2010 Mar 4.

16.

Thymidine kinase and deoxycytidine kinase in HIV-infected children.

Falasca F, Maida P, Boni A, Bernardi S, Cursi L, Rizzo B, Antonelli G, Gattinara GC, Turriziani O.

New Microbiol. 2009 Oct;32(4):411-3.

17.

[Plasma antiretroviral levels in children with human immunodeficiency virus infection. Influence of sex and age].

Nso-Roca AP, Larru B, Bellón JM, Mellado MJ, Ramos JT, González MI, Navarro ML, Muñoz-Fernández MA, de José MI.

Enferm Infecc Microbiol Clin. 2010 May;28(5):278-83. doi: 10.1016/j.eimc.2009.09.004. Epub 2010 Jan 25. Spanish.

PMID:
20097453
18.

Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS.

Pryce C, Pierre RB, Steel-Duncan J, Evans-Gilbert T, Palmer P, Moore J, Rodriguez B, Christie CD.

West Indian Med J. 2008 Jun;57(3):238-45.

PMID:
19583122
19.

Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Bertrand J, Comets E, Mentre F.

J Biopharm Stat. 2008;18(6):1084-102. doi: 10.1080/10543400802369012.

20.

Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.

Andrade AS, Hendrix C, Parsons TL, Caballero B, Yuan CS, Flexner CW, Dobs AS, Brown TT.

BMC Complement Altern Med. 2008 Aug 19;8:50. doi: 10.1186/1472-6882-8-50.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk